Study On The Mechanism Of Signals Transduction Of HIF-1α Facilitating The Human Umbilical Vein Endothelia Cells' Proliferation

IntroductionCoronary artery disease (CAD) is result of ischemia and hypoxia of myocardial cells. Now it is the first killer of human. The human is studying how to reconstitute the blood vessel. In recent years, with the progress in molecular biology, gene therapy for angiogenesis in ischemic myocardium has emerged as a novel promising approach in the coronary revascularization. Angiogenesis which can be generated in physiology and pathology process is new blood vessel growth from the origin capillary. In this process, many genes take part in vascular endothelial cells proliferation, vasoformation and maturation, for example, vascular endothelial growth factor (VEGF) and its receptor, fibroblast growth factor (FGF). Now VEGF and FGF had been used in clinical study. Although the phase I clinical trials have confirmed the safety and efficacy of their gene therapy, the phase II clinical trials have not got the same result. There were evidences indicated that VEGF gene therapy could result in vascular permeability, tissue edema etc and FGF therapy was associated with proteinuria. Vascular development is regulated by a series of growth factors. Single growth factor is not enough to induce mature angiogenesis. So hypoxia-induce factor 1 (HIF-1) initiated the human interest of studying.HIF-1 is a transcriptional factor that plays a key role in the cellular adaptive response to hypoxia and can regulate angiogenesis and erythropoiesis by modulating...